MBX Biosciences (NASDAQ:MBX) Shares Gap Down - Time to Sell?

Key Points

• MBX Biosciences' share price declined from a previous close of $20.10 to open at $17.60, showing a significant drop.
• Despite this decline, Wall Street Zen upgraded the company's rating from "sell" to "hold" on September 13th.
• The company's market capitalization stands at $589.84 million with a P/E ratio of -3.87.

MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report)'s share price gapped down prior to trading on Thursday . The stock had previously closed at $20.10, but opened at $17.60. MBX Biosciences shares last traded at $17.53, with a volume of 1,376,310 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded MBX Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, September 13th.

MBX Biosciences Stock Down 12.6%

The company has a market cap of $589.84 million and a P/E ratio of -3.87.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.